Division of Transplant Surgery, Department of Surgery, Mayo Clinic, Phoenix, Arizona, USA.
Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, Arizona, USA.
Am J Transplant. 2020 Dec;20(12):3582-3589. doi: 10.1111/ajt.16191. Epub 2020 Sep 27.
Outcomes of both donation after cardiac death (DCD) liver and kidney transplants are improving. Experience in simultaneous liver-kidney transplant (SLK) using DCD donors, however, remains limited. In an updated cohort (2010-2018), outcomes of 30 DCD SLK and 131 donation after brain death (DBD) SLK from Mayo Clinic Arizona and Mayo Clinic Minnesota were reviewed. The Model for End-Stage Liver Disease score was lower in the DCD SLK group (23 vs 29, P = .01). Kidney delayed graft function (DGF) rates were similar between the 2 groups (P = .11), although the duration of DGF was longer for DCD SLK recipients (20 vs 4 days, P = .01). Liver allograft (93.3% vs 93.1%, P = .29), kidney allograft (93.3% vs 93.1%, P = .91), and patient (96.7% vs 95.4%, P = .70) 1-year survival rates were similar. At 1 year, there were no differences in the estimated glomerular filtration rate (57.7 ± 18.2 vs 56.3 ± 17.7, P = .75) or progression of fibrosis (ci) on protocol kidney biopsy (P = .67). A higher incidence of biliary complications was observed in the DCD SLK group, with ischemic cholangiopathy being the most common (10.0% vs 0.0%, P = .03). The majority of biliary complications resolved with endoscopic management. With appropriate selection, DCD SLK recipients can have results equivalent to those of DBD SLK recipients.
心脏死亡后捐献(DCD)的肝和肾移植的效果都在改善。然而,使用 DCD 供体进行同时肝-肾移植(SLK)的经验仍然有限。在一个更新的队列(2010-2018 年)中,回顾了来自亚利桑那州梅奥诊所和明尼苏达州梅奥诊所的 30 例 DCD-SLK 和 131 例脑死亡后捐献(DBD)-SLK 的结果。DCD-SLK 组的终末期肝病模型评分较低(23 对 29,P=0.01)。两组间肾移植延迟功能恢复(DGF)的发生率相似(P=0.11),尽管 DCD-SLK 受者的 DGF 持续时间较长(20 对 4 天,P=0.01)。肝移植(93.3%对 93.1%,P=0.29)、肾移植(93.3%对 93.1%,P=0.91)和患者(96.7%对 95.4%,P=0.70)1 年生存率相似。在 1 年时,两组间估算肾小球滤过率(57.7±18.2 对 56.3±17.7,P=0.75)或方案性肾活检时纤维化进展(ci)(P=0.67)均无差异。DCD-SLK 组观察到更高的胆道并发症发生率,其中缺血性胆管病最为常见(10.0%对 0.0%,P=0.03)。大多数胆道并发症通过内镜治疗得到解决。通过适当的选择,DCD-SLK 受者可以获得与 DBD-SLK 受者相当的结果。